A glimpse into relapsed refractory multiple myeloma treatment in real-world practice in Spain: the GeminiS study
ABSTRACTObjectives: To describe the incorporation of monoclonal antibodies (mAb) in real-world (RW) practice for the treatment of patients with relapsed refractory multiple myeloma (RRMM) in a setting with other treatment alternatives.Methods: This was an observational, multicenter, ambispective stu...
Main Authors: | Rafael Ríos-Tamayo, Juan Alfons Soler, Ricarda García-Sánchez, Ernesto Pérez Persona, Mario Arnao, Antoni García-Guiñón, Abel Domingo, Miriam González-Pardo, Javier de la Rubia, María Victoria Mateos |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2023-12-01
|
Series: | Hematology |
Subjects: | |
Online Access: | https://www.tandfonline.com/doi/10.1080/16078454.2023.2178997 |
Similar Items
-
Outcomes of anti-CD38 isatuximab plus pomalidomide and dexamethasone in five relapsed myeloma patients with prior exposure to anti-C38 daratumumab: case series
by: Faouzi Djebbari, et al.
Published: (2022-12-01) -
Clinical Outcomes of Patients with Multiple Myeloma after Daratumumab Failure
by: Irene Zamanillo, et al.
Published: (2023-08-01) -
Role of daratumumab in relapsed or refractory multiple myeloma patient: A meta-analysis and literature to review
by: Abubakar Tauseef, et al.
Published: (2022-01-01) -
Evaluating Daratumumab in the Treatment of Multiple Myeloma: Safety, Efficacy and Place in Therapy
by: Dima D, et al.
Published: (2020-08-01) -
Phase II trial of daratumumab with DCEP in relapsed/refractory multiple myeloma patients with extramedullary disease
by: Ja Min Byun, et al.
Published: (2022-10-01)